Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.

4584Background: The therapeutic landscape for metastatic renal cell carcinoma (mRCC) has evolved rapidly with the approval of targeted therapies like tyrosine kinase-, mTOR-, multikinase-, and immu...